Maven Securities’s Denali Therapeutics DNLI Stock Holding History

Maven Securities’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-40,000	Closed	-$624K	–	70
2017 Q4	$624K	Buy	+40,000	New	+$719K	0.32%	35

Other funds holding DNLI

Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Maven Securities's DNLI Position: Q1 2018 in Review

Maven Securities sold out of Denali Therapeutics (DNLI) in Q1 2018, closing a stake of 40,000 shares — an estimated $624K sold.

Maven Securities first reported a position in DNLI in Q4 2017 and held it in 1 quarter. The position peaked at $624K in Q4 2017. 58 funds tracked by Wall St. Rank hold DNLI as of Q1 2018.

Maven Securities reported no remaining Denali Therapeutics position as of Q1 2018 after selling out during the quarter.
Maven Securities sold 40,000 Denali Therapeutics shares in Q1 2018, an estimated $624K.
Maven Securities first reported a position in Denali Therapeutics in Q4 2017 and held it in 1 quarter.
Maven Securities's Denali Therapeutics position peaked at $624K in Q4 2017.
58 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2018.

Based on Maven Securities's 13F filing for Q1 2018, filed 15 May 2018.